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Introduction: Idiopathic central serous chorioretinopathy (CSCR) is a relatively common 
ophthalmic disorder characterized by the development of a serous detachment of the sensory 
retina. Psychophysiological factors may trigger or maintain CSCR, though, surprisingly, the 
association between CSCR and anxiety has yet to be studied. The aims of the present study were 
threefold: to determine whether 1) Iranian patients with CSCR have higher scores for anxiety, 
2) anxiety is lower, if CSCR has been experienced twice, and whether 3) anxiety scores differ 
between sexes.
Methods: A total of 30 patients with CSCR and 30 healthy age- and sex-matched controls took 
part in the study. A brief face-to-face interview was conducted covering demographic variables 
and history and occurrence of CSCR and assessing anxiety.
Results: Compared to healthy controls, anxiety was significantly higher in both first-time and 
second-time CSCR patients. In CSCR patients, anxiety scores did not differ between sexes.
Conclusion: Higher anxiety scores were observed in Iranian patients with CSCR, irrespective of 
whether this was the first or second occurrence of CSCR. This suggests there is no psychological 
adaptation in terms of reduced anxiety among patients with repeated CSCR.
Keywords: idiopathic central serous chorioretinopathy, anxiety, Iranian population, healthy 
controls
Introduction
Central serous chorioretinopathy (CSCR) is a relatively common ophthalmic disorder 
characterized by the development of a serous detachment of the sensory retina due to 
a deficient pumping function at the retinal pigment epithelium level.1–3 Diagnosis of 
CSCR is made using fluorescein angiography, while retinal optical coherence tomog-
raphy can demonstrate shallow serous detachment.2,4 CSCR typically affects adults 
between 30 and 50 years of age. Symptomatic patients may experience sudden onset 
of dim and blurred vision, micropsia, metamorphopsia, decreased color vision, and 
central scotoma.5 Although the condition is normally unilateral, bilateral involvement 
have been reported in about 40% of cases.1,2 Further, CSCR typically occurs more 
frequently in young males than in females.3 Thus, males show a significantly higher 
mean annual incidence of CSCR than females, and the peak mean annual incidence 
occurs in men between 35 and 39 years.6 In most cases, CSCR is self-limiting and 
resolves spontaneously in 2–3 months, though usually without a complete recovery of 
visual function.3 Furthermore, some patients may suffer from persistent or recurrent 
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CSCR with subsequent progressive loss of vision.7 Recurrent 
CSCR is associated with a variety of psychiatric disorders.7 
Thus, the quality of life (QoL) of patients with CSCR may 
be compromised as a side effect of disturbing symptoms 
that occur during both acute and chronic phases of the 
disease.3
Neither the etiology nor the pathophysiology of CSCR is 
completely understood. Nonetheless, a range of psychologi-
cal and psychophysiological variables have been found to 
be associated with the occurrence of CSCR. For example, 
correlations of type A personality, systemic hypertension, 
and obstructive sleep apnea have been reported with CSCR 
disease.2,8 Further, almost half of patients with CSCR have 
been reported to use exogenous steroids.9 Other risk factors 
are pregnancy, use of antibiotics, antihistamines, alcohol, 
smoking, and respiratory diseases.10–16 Further, Conrad et al17 
showed that patients with CSCR were more stressed as a 
result of inadequate coping strategies and a higher incidence 
of physical complaints.
Several studies have shown that patients with CSCR 
have higher scores for psychopathological symptoms when 
compared to healthy controls.3,17 Conrad et al17 found that 
CSCR patients had significantly higher emotional distress 
as measured by the Global Severity Index compared to 
healthy controls. This may reflect inadequate coping strate-
gies, as indicated in higher levels of physical complaints in 
the patient group.17 Sahin et al3 found that CSCR patients 
had more marked psychological symptoms and poorer QoL 
than healthy control subjects. They also showed that the 
psychological status and QoL of CSCR patients varied with 
degree of loss of vision.3 Siguan and Aguilar5 found that 
patients with CSCR were more likely to display tendencies 
to schizophrenia (84%), hysteria (83%), depression (75%), 
psychopathic deviance (67%), and hypochondriasis (58%) 
than control groups. Piskunowicz et al concluded that com-
pared to healthy controls, patients with CSCR were more 
insecure, reported higher levels of frustration and higher 
levels of anticipatory anxiety.16 In another study, greater 
use of psychopharmacologic drugs was identified as an 
independent risk factor for the development of CSCR.6 In 
this study, not exposure to but intake of antianxiety drugs 
was predominantly observed in male participants.
Taken together, numerous studies show an association 
between the occurrence of CSCR and psychological and 
psychophysiological characteristics. Further, the study by 
Tsai et al6 indicated that CSCR may be associated with the 
use of antianxiety drugs, though, surprisingly, to the best of 
our knowledge, no study has yet examined the association 
between the occurrence of CSCR and anxiety. In this spe-
cific context, anxiety is understood as a psychobiological 
process with the following characteristics: emotions such 
as fears and worries; anticipation of the worst, irritability, 
feelings of tension, loss of interests, and inability to relax; 
cognitions including dysfunctional thoughts of not being able 
to cope with issues or catastrophizing; somatic complaints 
such as pains, aches, weakness, and flushes; physiological 
alterations such as gastrointestinal pain, high heart rate, 
respiratory symptoms, and genitourinary symptoms; and 
behavioral changes such as sighing and rapid respiration, 
hand tremor, fidgeting, and avoidance of situations which 
might reduce anxiety.
Given that CSCR is associated with dramatically 
impaired vision, a human being’s most important sense, we 
anticipate that CSCR will be associated with anxiety and 
believe this link should be investigated. We also believe 
that if CSCR is associated with anxiety, then this offers a 
good starting point for psychotherapeutic treatment, with 
cognitive-behavioral therapies (CBT) having proved effi-
cacious in the treatment of anxiety. Additionally, we note 
that CSCR is self-limiting and resolves spontaneously in 
2–3 months. Accordingly, treating CSCR-related anxiety 
should be particularly efficacious. Finally, if patients are 
experiencing CSCR for a second time, they should be aware 
that the condition is generally fully reversible, that it resolves 
spontaneously within 2–3 months, and, consequently, they 
should experience less anxiety.
As regards the relation between anxiety and sex, a recent 
review18 concluded that female adults were twice as likely 
as males to develop or display anxiety disorders (see also16). 
However, to our knowledge, it is unclear to what extent 
females suffering CSCR will also report greater anxiety. 
Accordingly, a further aim of the present study was to explore 
to what extent anxiety scores differ between male and female 
patients with CSCR.
Based on the literature, the following two hypotheses 
were formulated. First, we expected higher anxiety scores 
in patients with CSCR when compared with healthy con-
trols. Second, we expected lower anxiety scores in CSCR 
patients suffering from CSCR for a second time. We treated 
as exploratory the question of whether females with CSCR 
have higher anxiety scores than males with CSCR.
To address these research questions, a sample of Iranian 
patients with CSCR was assessed; a sex- and age-matched 
control group was assessed in parallel. Evidence concern-
ing patients with CSCR has predominantly been gathered 
in Western countries; with the present study, we aimed to 
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contribute to the research on CSCR with a non-Western 
sample.
Materials and methods
Procedure and samples
A total of 30 patients (mean age: 36.10 years, standard 
deviation =2.34; 43% female) suffering from CSCR were 
assessed in the Farshchian Hospital, Hamadan, Iran, 
between 2012 and 2013. Of these, 13 patients were suffer-
ing from CSCR for a second time. This sample therefore 
allowed exploration of anxiety as a function of number 
of occurrences of CSCR. In parallel, a control group was 
assessed (mean age: 35.90 years, standard deviation =2.30; 
t[58]=0.34, P=0.74, d=0.087; sex distribution: χ2[N=60, 
df=1]=0.28, P=0.60). These healthy controls were recruited 
via word-of-mouth-recommendation and via advertisements 
among staff members of the Farshchian Hospital. To avoid 
possible confounders, the control group was matched for 
sex, age, marital status, economic circumstances, edu-
cational level, and place of residence. Table 1 gives the 
demographic data and statistical comparisons between the 
three groups.
To gather demographic, CSCR-related and anxiety-
related data, the assessment of both patients and healthy 
controls involved a brief medical interview and medical 
analysis of CSCR, focusing on current and past CSCR 
(for patients only), and on anxiety. To assess CSCR, in 
addition to medical history records, an ophthalmologist 
not further involved in the study performed fluorescein 
angiography and optical coherence tomography. Further, 
unilateral or bilateral involvement and data on loss of visual 
acuity and duration were assessed. Patients with a first or 
second CSCR did not descriptively and statistically differ 
as regards sociodemographic variables, uni- versus bilat-
eral involvement, loss of acuity of the current CSCR, and 
duration of CSCR (see Table 1). A trained psychologist not 
further involved in the study performed the brief interview 
to assess anxiety (see below). All participants were fully 
informed about the purpose of the study, and provided writ-
ten informed consent. The study was approved by the Ethics 
Committee of the Hamadan University of Medical Sciences 
(Hamadan, Iran), and was conducted in accordance with the 
ethical standards laid down in the Declaration of Helsinki.
assessing severity of anxiety: experts’ 
ratings with the hamilton anxiety rating 
scale (haM-a)
The Hamilton Anxiety Rating Scale (HAM-A)19 is a rating 
scale consisting of 14 items focusing on symptoms of anxiety. 
Specifically, experts ask patients about anxious mood (wor-
ries, anticipation of the worst, fearful anticipation, irritabil-
ity), tension (feelings of tension, fatigability, startle response, 
moved to tears easily, trembling, feelings of restlessness, 
inability to relax), fears (of dark, of strangers, of being left 
alone, of animals, of traffic, of crowds), insomnia (difficulty 
falling asleep, broken sleep, unsatisfying sleep and fatigue on 
waking, dreams, nightmares, night terrors), intellectual dif-
ficulties (difficulty concentrating, poor memory), depressed 
mood (loss of interest, lack of pleasure in hobbies, depression, 
early waking, diurnal swing), somatic complaints (muscu-
lar pains and aches, twitching, stiffness, myoclonic jerks, 
grinding of teeth, unsteady voice, increased muscular tone), 
somatic complaints (sensory: tinnitus, blurring of vision, hot 
and cold flushes, feelings of weakness, pricking sensation), 
cardiovascular symptoms (tachycardia, palpitations, pain 
in chest, throbbing of vessels, fainting feelings, missing beat), 
Table 1 Demographic data of patients suffering from idiopathic CSCR (first or second time) and healthy controls
Groups Statistics
CSCR: first time CSCR: second time Controls
N=17 N=13 N=30
sex (female/male) 8/9 5/8 11/19 χ2(N=60, df=2)=0.45, P=0.93
age (years) M (sD) 36.06 (2.38) 36.06 (2.38) 35.90 (2.28) F(2, 59)=0.061, P=0.94
civil status (single/married) 10/7 8/5 20/10 χ2(N=60, df=2)=0.56, P=0.82
education (diploma/higher education) 9/8 8/5 11/19 χ2(N=60, df=2)=0.45, P=0.89
employment (unemployed/employed) 10/7 7/6 18/12 χ2(N=60, df=2)=0.89, P=0.65
residency (city/countryside) 12/5 13/0 24/6 χ2(N=60, df=2)=0.34, P=0.78
income (below/above 1mio rials) 2/15 2/13 3/27 χ2(N=60, df=2)=0.08, P=0.89
Unilateral versus bilateral involvement 11/6 10/3 – χ2(N=30, df=1)=1.01, P=79
Duration of cscr (months) M (sD) 4.51 (3.8) 3.83 (3.26) t(28)=0.98, P=0.69
same eye as before: yes/no – 10/3 –
Abbreviations: cscr, central serous chorioretinopathy; df, degrees of freedom.
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respiratory symptoms (pressure or constriction in the chest, 
choking feelings, sighing, dyspnea), gastrointestinal symp-
toms (difficulty in swallowing, wind abdominal pain, burning 
sensations, abdominal fullness, nausea, vomiting, stomach 
rumbling, looseness of bowels, loss of weight, constipation), 
genitourinary symptoms (frequency of micturition, urgency 
of micturition, amenorrhea, menorrhagia, development of 
frigidity, premature ejaculation, loss of libido, impotence), 
and autonomic symptoms (dry mouth, flushing, pallor, 
tendency to sweat, giddiness, tension headache, raising of 
hair). Experts also noted behavior at interview (fidgeting, 
restlessness, or pacing; tremor of hands; furrowed brow; 
strained face; sighing or rapid respiration; facial pallor; 
swallowing, etc).
Answers were scored on five-point Likert scales rang-
ing from 0 (not present) to 4 (very severe), with higher sum 
scores reflecting more severe anxiety (range: 0–56 points). 
The following categories were also defined: ,15 points indi-
cates mild anxiety, 15–28 points indicates moderate anxiety 
severity, 29–42 points indicates severe anxiety, and 43–56 
points indicates extremely severe anxiety. Reliability, valid-
ity, and sensitivity of the tool have been reported for the Farsi 
version.20 (Cronbach’s alpha of the present study: 0.91).
statistical analysis
To compare the demographic data of patients and healthy 
controls, two Student’s t-tests (age and duration of CSCR) 
and a series of χ2 tests were performed. CSCR-related infor-
mation between patients with one or with two occurrences 
of CSCR were compared with χ2 tests and t-tests. Next, an 
analysis of variance was performed with the factors Group 
(patients with CSCR for the first time; patients with CSCR 
for the second time; healthy controls) and Sex (female 
versus male), and with Hamilton Anxiety Scale scores as 
the dependent variable. To explore the association between 
anxiety scores and CSCR-related data (duration, loss of acu-
ity), Pearson’s correlations were performed.
For t-tests, Cohen’s d effect sizes were reported with the 
following indices: d,0.50: small effect, d,0.79: medium 
effect, and d.0.8: large effect. For analyses of variance, 
effect sizes were indicated with the partial eta-squared (η2), 
with 0.059$η2$0.01 indicating small, 0.139$η2$0.06 indi-
cating medium, and η2$0.14 indicating large effect sizes.
Results
hamilton anxiety rating scale scores
Table 2 reports all descriptive and statistical information for 
the Hamilton Anxiety Scale scores, separately for Group (con-
trols; patients: first CSCR; patients: second CSCR) and Sex 
(males versus females). Figure 1 shows the Hamilton Anxiety 
Rating Scale scores, separately for groups and sex.
Hamilton Anxiety Scale scores differed significantly 
between groups, with lower scores in the control group 
when compared to the two patient groups. There were no 
significant sex differences, and no significant Group by Sex 
interaction.
No statistically significant correlations were observed 
between the anxiety scores and the loss of acuity and duration 
of the current CSCR, the area of detachment, and the perme-
ability and dilatation of choroid (ie, choroidal homeostasis; 
all rs,0.11, ps.0.60).
Discussion
The key findings of the present study were that, compared 
to healthy controls, patients suffering from idiopathic CSCR 
experienced higher anxiety, that anxiety in patients with 
CSCR was higher irrespective of whether CSCR was expe-
rienced for the first or for the second time, and that anxiety 
scores did not differ between males and females. The present 
study adds to the literature on CSCR and psychological func-
tioning in an important way in showing that the occurrence 
of CSCR was associated with anxiety.
Two hypotheses and one exploratory research question 
were formulated, and each of these is considered in turn.
Table 2 Overview of the descriptive and statistical statistics of hamilton anxiety scale scores for the factors group (patients with 
first- versus second-time idiopathic CSCR versus healthy controls) and Sex (females versus males)
Groups
Patients: first CSCR Patients: second CSCR Controls
N 17 N 13 N 30
Females M (sD) 8 29.25 (11.39) 5 30.80 (9.26) 11 10.60 (4.67)
Males M (sD) 9 26.89 (11.73) 8 23.75 (9.62) 19 12.83 (7.089)
statistics Factor group: F(2, 54)=25.47, P=0.000, partial eta-squared =0.485 (l)
Factor sex: F(1, 54)=0.86, P=0.357, partial eta-squared =0.016 (s)
Factor group by sex interaction: F(2, 54)=1.40, P=0.25, partial eta-squared =0.049 (s)
Note: indices are means and standard deviations are in parentheses.
Abbreviations: cscr, central serous chorioretinopathy; l, large effect size; s, small effect size.
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Our first hypothesis was that patients with CSCR would 
have higher scores for anxiety than healthy controls, and this 
hypothesis was fully confirmed. This result is consistent with 
the pattern of previous findings showing that occurrence of 
CSCR is associated with psychological issues.3,7,16,17 However, 
the present study adds to the current literature in an impor-
tant new way; it is the first demonstration of a link between 
CSCR and the experience of anxiety. We believe this result 
is noteworthy for at least three reasons. First, if it is accepted 
that vision is the most important of human senses, it is not sur-
prising that impairment of vision is associated with anxiety, 
that is, with the subjective experience of threat and danger. 
Second, given that vision is of overwhelming importance to 
human survival,21 it seems somewhat surprising that, to our 
knowledge, there has not previously been any investigation 
of the association between CSCR and anxiety. Third, indirect 
evidence for an association between anxiety and CSCR is 
provided by the observation that abuse of anxiolytics seems 
common among patients suffering from CSCR (Tsai et al6), 
suggesting that anxiety is a major concern among such 
patients. Overall, in our opinion, the present results might be 
considered an advance in the understanding of psychological 
processes and concerns among patients with CSCR.
Our second hypothesis was that anxiety would be lower 
among patients suffering from CSCR for the second time 
than among first-time sufferers. However, this hypothesis 
was not supported. This suggests that experiencing CSCR 
for a second time is not associated with an appreciation that 
CSCR is a transitory, treatable, and readily manageable 
impairment of vision. Unfortunately, the present data do not 
provide any deeper insight into patients’ cognitive and emo-
tional processes. Specifically, it was not clear why patients 
suffering from CSCR for a second time did not display 
more optimism and confidence about improvement in their 
condition, given that, in all patients suffering from CSCR 
for a second time, no residual or irreversible impairments of 
the ocular apparatus have been observed or reported in the 
ophthalmologic records. In other words, why had patients not 
learned from their first experience that suffering CSCR for a 
second time was no reason for fear? Again, the present data 
do not shed any light on the underlying cognitive–emotional 
mechanisms. Though highly speculative, we advance the 
following explanation. First, evidence shows that anxiety is 
a psychiatric disorder, which normally requires psychophar-
macological and psychotherapeutic treatment. Accordingly, it 
is unlikely that anxiety would disappear without professional 
treatment and on the basis of “mere” experience. Second, 
by definition, anxiety is fueled by dysfunctional emotional 
and cognitive processes such as catastrophizing thinking 
and negative expectations, often built up over a long period 
of time. Accordingly, it is unlikely that experiencing CSCR 
for “only” the second time would be sufficient not to trigger 
anxiety again. Most importantly, this assumption is further 
supported by the observation that no meaningful associations 
between anxiety scores and loss of acuity and duration of the 
current CSCR, the area of detachment, and the permeability 
and dilatation of of choroid vessels (ie, choroidal homeosta-
sis) could be observed. Third, if we take into account that 
patients suffering from CSCR might also have personality 
traits such as type A personality and low stress tolerance,16,17 
the underlying common factor might be anxiety. Fourth, 
given that CSCR might also be associated with subsequent 
partial loss of vision,7 fear of losing vision when CSCR 
occurs for a second time is not surprising. Finally, given 
that the recurrence of CSCR might also be associated with 
impaired QoL3 and increased risk of suffering from psychi-
atric disorders,7 the persistence of anxiety is consistent with 
the cognitive–emotional framework surrounding impaired 
QoL and psychiatric disorders. In our view, several factors 
in combination are likely to ensure that anxiety is not lower 
when experiencing CSCR for a second time.
Last, we treated as exploratory the question as to whether 
female patients with CSCR would exhibit higher anxiety 
scores than male patients. It has been observed that, compared 
to adult males, adult females are one-and-a-half to two times 
more likely to suffer from anxiety.18 However, in the pres-
ent study, we found no such difference. Accordingly, these 
results add to the current literature in a further important 
way by indicating that anxiety associated with CSCR is not 
sex-biased.
Despite the intriguing results, several limitations warn 
against overgeneralizing the results. First, the sample size 
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Figure 1 hamilton anxiety scale scores for different groups separated by sex.
Notes: Hamilton Anxiety Rating Scale scores differed statistically significantly 
(*) between healthy controls and patients with central serous chorioretinopathy, 
irrespective of whether patients suffered for the first or second time. No sex 
differences were observed. Bars are means; lines are standard deviations.
Abbreviation: cscr, central serous chorioretinopathy.
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was small, though the statistical indices focused on effect 
sizes, which are not sensitive to sample size. Second, data 
were gathered at one study center and a systematic bias in 
data collection and sample is therefore possible. Third, and 
most importantly, we considered only anxiety. Whereas 
assessing anxiety in patients with CSCR was the key focus 
of the present study, we are fully aware that anxiety might 
be a comorbid symptom of further underlying dysfunctional 
cognitive–emotional processes such as personality traits and 
psychiatric disorders. Future studies should therefore include 
a thorough psychiatric assessment. Fourth, in this respect, fur-
ther unassessed but latent psychophysiological factors might 
have biased two or more dimensions in the same direction.
Conclusion
Among patients suffering from CSCR, anxiety is substan-
tially higher than in healthy controls. Anxiety scores were not 
lower if CSCR was experienced for a second time, suggesting 
therefore that no psychophysiological adaptation occurs with 
repetition of CSCR.
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